Pagoclone
Cas No.: 133737-48-1
What is Pagoclone?
Pagoclone (2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-dihydro-3-(5-methyl-2-oxo hexyl)-1H-isoindole-1-one) is a compound initially developed as an anti-anxiety drug. It is classified as a cyclopyrrolone derivative drug. This substance is referred to as a nonbenzodiazepine – it exhibits effects similar to benzodiazepines, but has a different chemical structure. Like other drugs in the benzodiazepine group, it interacts with GABA A receptors, showing anti-anxiety effects, but not excessive sedative effects.
Pagoclone application
The prepper is used to relieve anxiety. They allow you to calm down and calm down. It makes it easier to fall asleep, but does not cause excessive daytime sleepiness. Most importantly – the product does not have a strong sedative effect, so its use is not accompanied by excessive subduedness or confusion. Pagoclon, therefore, does not adversely affect daily functioning, does not impede the performance of duties by way of the appearance of drowsiness or suppression of sharp thinking.
Another profile of the product is its use to alleviate the symptoms of stuttering.
Mechanism of action
The compound interacts with GABA A receptors, more specifically, the alpha2 and alpha3 subunits. These subunits are responsible for the anti-anxiety effects of benzodiazepines. In contrast, the product shows virtually no activity against the alpha1 subunit of GABA A receptors. And that means no strong sedative or sleep-inducing effects.
Pagoclon dosage
It is recommended to take the product at a dose of 0.3 go 1.2 mg per day.
References:
- de Wit H, Vicini L, Haig GM, Hunt T, Feltner D: Evaluation of the abuse potential of pagoclone, a partial GABAA agonist. J Clin Psychopharmacol. 2006 Jun;26(3):268-73; https://go.drugbank.com/articles/A2905
- Atack JR, Pike A, Marshall G, Stanley J, Lincoln R, Cook SM, Lewis RT, Blackaby WP, Goodacre SC, McKernan RM, Dawson GR, Wafford KA, Reynolds DS: The in vivo properties of pagoclone in rat are most likely mediated by 5′-hydroxy pagoclone. Neuropharmacology. 2006 May;50(6):677-89. Epub 2006 Jan 20; https://go.drugbank.com/articles/A2906
- Bateson A: Pagoclone Indevus. Curr Opin Investig Drugs. 2003 Jan;4(1):91-5; https://pubmed.ncbi.nlm.nih.gov/12625036/
- Sandford JJ, Forshall S, Bell C, Argyropoulos S, Rich A, D’Orlando KJ, Gammans RE, Nutt DJ: Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharmacol. 2001 Sep;15(3):205-8; https://pubmed.ncbi.nlm.nih.gov/11565630/
